Physician profile
Matthew Leonard
NPI 1699846071
$4,439.14
in general payments reported to CMS, 2019-2025
21 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $1,289 · 2023: $1,205 · 2024: $1,296 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $718.70 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $708.59 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $563.18 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.28 | 2022-2024 | Caplyta |
| Alkermes, INC. | $352.42 | 2021-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $352.07 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $323.89 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $265.83 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $148.88 | 2023-2024 | Austedo Xr, Austedo, Uzedy |
| Corium, LLC | $138.60 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $123.49 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $70.14 | 2023-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $45.04 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $41.56 | 2022 | |
| Supernus Pharmaceuticals, INC. | $39.20 | 2022-2024 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.73 | 2023 | Spravato |
| Owp Pharmaceuticals, INC. | $25.37 | 2022 | |
| Eisai INC. | $24.59 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.71 | 2024 | Quviviq |
| Bausch Health US, LLC | $16.72 | 2022 | |
| Noven Therapeutics, LLC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.